IN2014MN02304A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02304A IN2014MN02304A IN2304MUN2014A IN2014MN02304A IN 2014MN02304 A IN2014MN02304 A IN 2014MN02304A IN 2304MUN2014 A IN2304MUN2014 A IN 2304MUN2014A IN 2014MN02304 A IN2014MN02304 A IN 2014MN02304A
- Authority
- IN
- India
- Prior art keywords
- gip
- glp
- assessed
- substitutions
- activity
- Prior art date
Links
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940125542 dual agonist Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642439P | 2012-05-03 | 2012-05-03 | |
| US201361765561P | 2013-02-15 | 2013-02-15 | |
| PCT/EP2013/059319 WO2013164483A1 (en) | 2012-05-03 | 2013-05-03 | Gip-glp-1 dual agonist compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02304A true IN2014MN02304A (enExample) | 2015-08-07 |
Family
ID=48325702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2304MUN2014 IN2014MN02304A (enExample) | 2012-05-03 | 2013-05-03 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10100097B2 (enExample) |
| EP (1) | EP2844669B1 (enExample) |
| JP (1) | JP6228187B2 (enExample) |
| KR (1) | KR102184241B1 (enExample) |
| CN (1) | CN104470948B (enExample) |
| AR (1) | AR090937A1 (enExample) |
| AU (1) | AU2013255751B2 (enExample) |
| BR (1) | BR112014027348B1 (enExample) |
| CA (1) | CA2872314C (enExample) |
| EA (1) | EA028665B1 (enExample) |
| HK (1) | HK1208232A1 (enExample) |
| IL (1) | IL235463A0 (enExample) |
| IN (1) | IN2014MN02304A (enExample) |
| MX (1) | MX356641B (enExample) |
| NZ (1) | NZ702333A (enExample) |
| PH (1) | PH12014502452A1 (enExample) |
| SG (1) | SG11201407137PA (enExample) |
| TR (1) | TR201815338T4 (enExample) |
| TW (1) | TWI689515B (enExample) |
| WO (1) | WO2013164483A1 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
| WO2013164483A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014096179A1 (en) * | 2012-12-19 | 2014-06-26 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
| SG10201705097PA (en) * | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| SI3057984T1 (sl) | 2013-10-17 | 2018-10-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| US10093713B2 (en) * | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| TWI705973B (zh) * | 2014-10-29 | 2020-10-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ促效劑化合物及方法 |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| TWI707867B (zh) | 2015-04-16 | 2020-10-21 | 丹麥商西蘭製藥公司 | 醯化之昇糖素類似物 |
| CA2997343A1 (en) | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| CN109477094B (zh) * | 2016-05-24 | 2022-04-26 | 武田药品工业株式会社 | 肽化合物 |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| US10577905B2 (en) | 2018-02-12 | 2020-03-03 | Eagle Technology, Llc | Hydrocarbon resource recovery system and RF antenna assembly with latching inner conductor and related methods |
| EP3773475A1 (en) | 2018-04-06 | 2021-02-17 | Cyprumed GmbH | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| TWI707865B (zh) * | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| MA53390A (fr) | 2018-07-23 | 2021-06-02 | Lilly Co Eli | Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie |
| WO2020023386A1 (en) | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Gip/glp1 co-agonist compounds |
| MA53378A (fr) | 2018-07-23 | 2021-06-02 | Lilly Co Eli | Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète |
| EP3856768A2 (en) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| CN113614102B (zh) * | 2019-01-07 | 2024-08-13 | 鸿绪生物医药科技（北京）有限公司 | 新型多肽及其治疗用途 |
| CA3136163A1 (en) * | 2019-04-11 | 2020-10-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Multi-receptor agonist and medical use thereof |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| JP2022545200A (ja) | 2019-08-19 | 2022-10-26 | イーライ リリー アンド カンパニー | インクレチン類似体を作製する方法 |
| CN114786706A (zh) | 2019-10-04 | 2022-07-22 | 韩美药品株式会社 | 胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| PE20221168A1 (es) | 2019-11-11 | 2022-07-25 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
| CN113383014B (zh) * | 2019-11-15 | 2024-06-18 | 江苏豪森药业集团有限公司 | 双受体重激动剂化合物及其药物组合物 |
| JP7788376B2 (ja) * | 2019-12-03 | 2025-12-18 | アンタグ セラピューティクス エーピーエス | 最適化されたｇｉｐペプチド類縁体 |
| WO2021143810A1 (zh) * | 2020-01-17 | 2021-07-22 | 珠海联邦制药股份有限公司 | 多肽化合物及其应用 |
| MX2022009149A (es) * | 2020-01-23 | 2022-12-15 | Lilly Co Eli | Compuestos coagonistas de gip/glp1. |
| TW202228762A (zh) | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| AU2021241257A1 (en) * | 2020-03-25 | 2022-10-13 | Takeda Pharmaceutical Company Limited | QD dosing of GIP receptor agonist peptide compounds and uses thereof |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| WO2022018185A1 (en) | 2020-07-22 | 2022-01-27 | Novo Nordisk A/S | Glp-1 and gip receptor co-agonists |
| CA3184717A1 (en) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| WO2022049310A1 (en) | 2020-09-07 | 2022-03-10 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
| EP4204440A1 (en) * | 2020-10-17 | 2023-07-05 | Sun Pharmaceutical Industries Limited | Glp-1/gip dual agonists |
| CN116615222A (zh) * | 2020-12-02 | 2023-08-18 | 东宝紫星(杭州)生物医药有限公司 | 含内酰胺修饰的多肽类化合物 |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| EP4249505A4 (en) * | 2020-12-23 | 2024-08-21 | Zhejiang Doer Biologics Co., Ltd. | GLUCAGONE DERIVATIVE WITH LONG-TERM EFFECTS |
| EP4281464A4 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| MX2023013144A (es) | 2021-05-07 | 2023-11-28 | Lilly Co Eli | Tableta erosionable. |
| CN117866048A (zh) * | 2021-05-28 | 2024-04-12 | 广东众生睿创生物科技有限公司 | 多肽的制备及其应用 |
| WO2022253202A1 (zh) * | 2021-06-01 | 2022-12-08 | 南京知和医药科技有限公司 | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 |
| WO2023030444A1 (zh) * | 2021-09-02 | 2023-03-09 | 广东东阳光药业有限公司 | Glp-1/gip双靶多肽、融合蛋白及其应用 |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| US20250115654A1 (en) * | 2021-11-12 | 2025-04-10 | Fujian Shengdi Pharmaceutical Co., Ltd. | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN116947978A (zh) * | 2022-04-19 | 2023-10-27 | 北京惠之衡生物科技有限公司 | 一种glp-1和gip受体共激动多肽衍生物及其盐和制剂 |
| CN119522233A (zh) | 2022-07-13 | 2025-02-25 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| WO2024015922A2 (en) * | 2022-07-15 | 2024-01-18 | Pep2Tango Therapeutics Inc. | Compositions including multi-agonist peptides and methods of manufacture and use |
| CA3262093A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical Formulations and Methods for the Treatment of Metabolic and Liver Disorders |
| EP4580608A1 (en) | 2022-08-29 | 2025-07-09 | Eli Lilly And Company | Compositions for oral delivery |
| JP2025531200A (ja) | 2022-09-15 | 2025-09-19 | イーライ リリー アンド カンパニー | Ｇｉｐ及びｇｌｐ－１二重アゴニスト化合物 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| AU2023415591A1 (en) | 2022-12-30 | 2025-08-14 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| PE20252287A1 (es) | 2023-01-31 | 2025-09-18 | Lilly Co Eli | Agonistas del trirreceptor gip/glp1/gcg y usos de estos |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4687947A1 (en) | 2023-04-05 | 2026-02-11 | Antag Therapeutics ApS | Gip activity modulators and orthostatic intolerance |
| EP4714434A1 (en) | 2023-05-19 | 2026-03-25 | Aulbio Co., Ltd. | Microsphere comprising thyrazepatide, method for preparing same, and pharmaceutical composition comprising same |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| TW202517291A (zh) | 2023-06-30 | 2025-05-01 | 丹麥商西蘭製藥公司 | 組合療法 |
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| CN117646017A (zh) * | 2023-11-02 | 2024-03-05 | 中国人民解放军海军军医大学 | Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用 |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| NZ334595A (en) | 1996-09-09 | 2000-08-25 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| WO1999025727A2 (en) | 1997-11-14 | 1999-05-27 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| JP4394279B2 (ja) | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| CN1495198A (zh) | 1998-12-07 | 2004-05-12 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 胰高血糖素样肽-1的类似物 |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| PL351326A1 (en) | 1999-03-17 | 2003-04-07 | Novo Nordisk As | Method for acylating peptides and novel acylating agents |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US20060217290A1 (en) | 2003-04-29 | 2006-09-28 | Kohn Wayne D | Insulin analogs having protracted time action |
| CN106137952B (zh) | 2004-11-12 | 2020-11-17 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| CN101155828A (zh) * | 2005-02-11 | 2008-04-02 | 安米林药品公司 | Gip类似物和具有可选择性质的杂合多肽 |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2006121860A2 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
| WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| CN101432025B (zh) * | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
| NZ574215A (en) | 2006-07-18 | 2012-07-27 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| ITMI20061607A1 (it) | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
| US20090318353A1 (en) * | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| ES2554773T3 (es) | 2006-10-04 | 2015-12-23 | Case Western Reserve University | Insulina y análogos de la insulina resistentes a la fibrilación |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| JP6017754B2 (ja) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
| DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
| US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| PL2229407T3 (pl) | 2008-01-09 | 2017-06-30 | Sanofi-Aventis Deutschland Gmbh | Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| NZ586589A (en) | 2008-01-09 | 2012-04-27 | Sanofi Aventis Deutschland | Novel insulin analogues having an extremely delayed time-action profile |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| CN102065885A (zh) | 2008-04-22 | 2011-05-18 | 卡斯西部储备大学 | 同种型特异性的胰岛素类似物 |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| BRPI0915282A2 (pt) * | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| KR20110061552A (ko) | 2008-07-31 | 2011-06-09 | 케이스 웨스턴 리저브 유니버시티 | 할로겐 안정화된 인슐린 |
| EP2328922A4 (en) * | 2008-08-07 | 2013-01-02 | Ipsen Pharma Sas | ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE |
| CN106317164A (zh) | 2008-09-12 | 2017-01-11 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| WO2010070252A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| JP5635529B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| NZ593813A (en) | 2008-12-15 | 2013-02-22 | Zealand Pharma As | Glucagon analogues |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| WO2010080606A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Insulin analogs |
| US20100240883A1 (en) | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
| CN104327182B (zh) | 2009-12-16 | 2020-04-17 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
| JP2013517307A (ja) | 2010-01-20 | 2013-05-16 | ジーランド ファーマ アクティーゼルスカブ | 心臓病の処置 |
| RU2012136450A (ru) * | 2010-01-27 | 2014-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2011117417A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
| RU2531590C2 (ru) | 2010-04-27 | 2014-10-20 | Бета Фармасьютикалс,Ко,Лтд. | Аналоги глюкагоноподобного пептида-1 и их применение |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| EP2585482B1 (en) | 2010-06-24 | 2019-03-27 | Zealand Pharma A/S | Glucagon analogues |
| CN105601729A (zh) | 2010-11-09 | 2016-05-25 | 诺沃—诺迪斯克有限公司 | 双-酰化的glp-1衍生物 |
| MA34913B1 (fr) | 2011-01-20 | 2014-02-01 | Zealand Pharma As | Combinaison d'analogues du glucagon acylé à des analogues d'insuline |
| KR20140020292A (ko) | 2011-03-28 | 2014-02-18 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
| KR101972836B1 (ko) | 2011-04-12 | 2019-04-29 | 노보 노르디스크 에이/에스 | 이중 아실화된 ｇｌｐ-1 유도체 |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| WO2012167744A1 (en) * | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| JP6352806B2 (ja) | 2011-09-23 | 2018-07-04 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| SG11201403377QA (en) | 2011-12-23 | 2014-07-30 | Zealand Pharma As | Glucagon analogues |
| WO2013164483A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| SI3057984T1 (sl) | 2013-10-17 | 2018-10-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| AR100306A1 (es) | 2014-02-18 | 2016-09-28 | Novo Nordisk As | Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia |
| TWI707867B (zh) | 2015-04-16 | 2020-10-21 | 丹麥商西蘭製藥公司 | 醯化之昇糖素類似物 |
-
2013
- 2013-05-03 WO PCT/EP2013/059319 patent/WO2013164483A1/en not_active Ceased
- 2013-05-03 HK HK15108788.2A patent/HK1208232A1/xx unknown
- 2013-05-03 MX MX2014013318A patent/MX356641B/es active IP Right Grant
- 2013-05-03 AU AU2013255751A patent/AU2013255751B2/en active Active
- 2013-05-03 TW TW102115949A patent/TWI689515B/zh active
- 2013-05-03 CA CA2872314A patent/CA2872314C/en active Active
- 2013-05-03 AR ARP130101524A patent/AR090937A1/es unknown
- 2013-05-03 EA EA201491918A patent/EA028665B1/ru not_active IP Right Cessation
- 2013-05-03 BR BR112014027348-0A patent/BR112014027348B1/pt active IP Right Grant
- 2013-05-03 US US14/398,260 patent/US10100097B2/en active Active
- 2013-05-03 TR TR2018/15338T patent/TR201815338T4/tr unknown
- 2013-05-03 KR KR1020147033952A patent/KR102184241B1/ko active Active
- 2013-05-03 NZ NZ702333A patent/NZ702333A/en unknown
- 2013-05-03 IN IN2304MUN2014 patent/IN2014MN02304A/en unknown
- 2013-05-03 JP JP2015509461A patent/JP6228187B2/ja active Active
- 2013-05-03 SG SG11201407137PA patent/SG11201407137PA/en unknown
- 2013-05-03 EP EP13720931.8A patent/EP2844669B1/en active Active
- 2013-05-03 CN CN201380032714.4A patent/CN104470948B/zh active Active
-
2014
- 2014-11-02 IL IL235463A patent/IL235463A0/en unknown
- 2014-11-03 PH PH12014502452A patent/PH12014502452A1/en unknown
-
2018
- 2018-09-05 US US16/121,745 patent/US20190135886A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI689515B (zh) | 2020-04-01 |
| NZ702333A (en) | 2017-06-30 |
| US20190135886A1 (en) | 2019-05-09 |
| PH12014502452A1 (en) | 2015-02-02 |
| TW201348252A (zh) | 2013-12-01 |
| SG11201407137PA (en) | 2014-11-27 |
| TR201815338T4 (tr) | 2018-11-21 |
| CN104470948A (zh) | 2015-03-25 |
| JP6228187B2 (ja) | 2017-11-08 |
| AU2013255751A1 (en) | 2014-12-18 |
| WO2013164483A1 (en) | 2013-11-07 |
| EA201491918A1 (ru) | 2015-07-30 |
| US10100097B2 (en) | 2018-10-16 |
| US20150299281A1 (en) | 2015-10-22 |
| CA2872314A1 (en) | 2013-11-07 |
| AU2013255751B2 (en) | 2017-10-05 |
| KR20150003910A (ko) | 2015-01-09 |
| BR112014027348B1 (pt) | 2022-12-20 |
| IL235463A0 (en) | 2014-12-31 |
| CA2872314C (en) | 2021-08-31 |
| MX2014013318A (es) | 2015-09-28 |
| CN104470948B (zh) | 2018-06-15 |
| JP2015517459A (ja) | 2015-06-22 |
| HK1208232A1 (en) | 2016-02-26 |
| BR112014027348A2 (pt) | 2017-06-27 |
| AR090937A1 (es) | 2014-12-17 |
| EA028665B1 (ru) | 2017-12-29 |
| MX356641B (es) | 2018-06-07 |
| EP2844669A1 (en) | 2015-03-11 |
| KR102184241B1 (ko) | 2020-12-01 |
| EP2844669B1 (en) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02304A (enExample) | ||
| MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
| MX384253B (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
| MX361862B (es) | Composiciones y métodos que comprenden variante de enzima lipolítica. | |
| PH12014501653A1 (en) | Metalloenzyme inhibitor compounds | |
| WO2012140274A3 (en) | Agonists and antagonists of the wnt pathway | |
| PH12013500360B1 (en) | Pesticidal compositions | |
| MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
| MY173521A (en) | Trpv4 antagonists | |
| MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
| WO2013123046A3 (en) | Cathode buffer materials and related devices and methods | |
| IN2014CN04050A (enExample) | ||
| IN2014DN11078A (enExample) | ||
| MX2019013560A (es) | Formulaciones con oxidacion reducida. | |
| MX2015011433A (es) | Formulaciones con oxidacion reducida. | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| MA40027A (fr) | Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique | |
| IN2015DN02646A (enExample) | ||
| IN2013MU02208A (enExample) | ||
| IN2015KN00386A (enExample) | ||
| IN2015DN02647A (enExample) | ||
| GB201716059D0 (en) | Compounds to inhibit S-layer assembly in bacillus anthracis | |
| UA105703C2 (uk) | 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти | |
| UA96060C2 (ru) | Применение липофлавона как средства фригопротекторного действия |